Spruce Street Capital »

Erasca shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Erasca (ERAS) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Erasca

Tip: Access up to 7 years of quarterly data

All positions including Erasca held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Erasca by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $7.7M 423k 18.32

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Erasca

Frazier Life Sciences Management
BlackRock
VR Adviser
Rtw Investments
Vivo Capital
Vanguard Capital Management
Siren
Logos Global Management
Paradigm Biocapital Advisors
State Street Corporation
Arch Venture Corp
Geode Capital Management
Cormorant Asset Management
Affinity Asset Advisors
Balyasny Asset Management

View all funds holding Erasca